Prognostic AI Advantage Altis Labs leverages IPRO, an imaging-based prognostication platform trained on the industry’s largest cancer-imaging database with longitudinal context, to help biopharma optimize trial design and accelerate approvals. The tool predicts patient outcomes beyond tumor size, supporting smarter trial endpoints and reduced time, cost, and trial risk.

External Control Opportunity With the External Control Arm offering and real-world digital twin capabilities, Altis can help sponsors enrich control arms using real-world data to lower trial size, shorten timelines, and improve statistical power. This approach is being showcased through recent work with external control methodologies at industry events.

Strategic Partnerships Ongoing collaborations with leading cancer centers such as University Health Network and active participation in major oncology forums position Altis as a credible, co-development partner for multi-year data-sharing and integrated AI imaging solutions.

Market Expansion Potential Global pharma interest and conference activity position Altis to scale beyond current revenue, targeting international biopharma and cancer centers that require AI-driven trial design and prognostication backed by a large cancer-imaging dataset.

Competitive Differentiation IPRO delivers prognostic insights beyond conventional tumor metrics, enabling more accurate outcome prediction and patient stratification, differentiating Altis from traditional imaging tools and supporting more efficient, evidence-based trial design.